Maravai LifeSciences, Inc. announced plans for William Trey Martin, III to serve as President of Maravai's Biologics Safety Testing Segment beginning December 5, 2022, and Christine Dolan, the current Chief Operating Officer of Maravai's Biologics Safety Testing Segment, will continue to serve in that role and will report to Martin. Carl Hull, Maravai's co-founder, will continue to serve as Maravai's Executive Chairman.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.05 USD | +0.91% | -1.34% | +68.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.70% | 1.47B | |
-27.70% | 9.87B | |
+27.06% | 2.89B | |
-16.78% | 2.75B | |
-15.31% | 2.13B | |
-21.41% | 1.65B | |
+29.75% | 811M | |
-5.02% | 733M | |
-29.39% | 510M | |
+1.59% | 300M |
- Stock Market
- Equities
- MRVI Stock
- News Maravai LifeSciences Holdings, Inc.
- Maravai LifeSciences Holdings, Inc. Announces William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment, Effective December 5, 2022